Eplecard 25mg Tablet contains Eplerenone, a selective aldosterone receptor antagonist indicated primarily for the treatment of hypertension and heart failure post-myocardial infarction. By competitively blocking aldosterone receptors in the distal renal tubules, Eplerenone promotes sodium and water excretion while conserving potassium, thereby reducing blood volume and systemic vascular resistance. This mechanism contributes to improved cardiac remodeling and reduced morbidity and mortality in patients with left ventricular dysfunction following acute myocardial infarction. Eplecard is administered orally, with a recommended dose of 25mg once daily, which may be adjusted based on clinical response and serum potassium levels. It is contraindicated in patients with hyperkalemia, severe renal impairment, or hypersensitivity to the drug. Caution is advised when co-administered with potassium-sparing diuretics, potassium supplements, or other agents that increase serum potassium, to prevent hyperkalemia. Regular monitoring of renal function and electrolytes is essential during therapy. Eplecard is generally well tolerated, with adverse effects including dizziness, hyperkalemia, and gastrointestinal disturbances. This medication should be used under medical supervision, with adherence to prescribed dosing and monitoring guidelines to optimize therapeutic outcomes and minimize risks.